Since the World Health Organisation declared COVID-19 a global pandemic, the number of hospitalisations and deaths caused by the virus has significantly increased. As additional Omicron sub-variants emerge, the likelihood of transmission increases, necessitating the need for new combination therapy to reduce the risk of coronavirus development. In this case, strengthening the immune system is essential to fight against extremely inflammatory diseases such as the cytokine storm caused by the coronavirus. In addition, monoclonal antibodies (mAbs) that neutralise SARS-CoV-2 can reduce the risk of hospitalization if administered early in COVID-19 illness. One such mAb that recently gained consideration is LY-CoV1404 (bebtelovimab), which neutralises the SARS-CoV-2 virus and protects binding to the spike proteins of multiple variants, including B.1.1.529 (Omicron) and its subvariants (BA.1, BA.1.1, and BA.2) with different essential receptor binding domain (RBD) mutations. The benefits of melatonin in conjunction with bebtelovimab, the most potent SARS-CoV-2 neutralising monoclonal antibody against the Omicron form in the treatment of COVID-19, are highlighted in this brief overview. According to this study, the combination therapy is beneficial for the Omicron sub-variants and may be used as an adjuvant therapy for the coronavirus.
